Spread the love Table of Contents Introduction Methodology Top 10 Biotech Giants Rising Stars (11-25) Innovators and ...

Sage Chief Medical Officer Laura Gault, M.D., Ph.D., is stepping down to pursue a new opportunity effective March 21, the ...

As Sage Therapeutics Inc. contemplates its path forward after rejecting a buyout offer from Biogen, its top executive ...

Sage Therapeutics (SAGE) announced that Dr. Laura Gault, Chief Medical Officer, has decided to pursue a new opportunity and will depart the ...

US-based Praxis Precision has decided not to halt its Phase III trial examining its essential tremor (ET) therapy after an ...

We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at ...

Learn more about whether Biogen Inc. or Insmed Incorporated is a better investment based on AAII's A+ Investor grades, which ...

Biogen and Stoke Therapeutics have reached an agreement to develop and commercialize zorevunersen, a potential first-in-class disease-modifying therapy for Dravet syndrome, in all regions outside of ...

Biogen and Stoke Therapeutics have agreed to collaborate on Stoke's proposed zorevunersen treatment for the severe genetic epilepsy Dravet syndrome in a deal potentially worth hundreds of millions ...

Biogen secures rights to commercialize zorevunersen ... support the company through to mid-2028,” said Edward Kaye, CEO of Stoke Therapeutics. Price Action: At last check Tuesday, BIIB was ...

On Tuesday, Biogen Inc. (NASDAQ:BIIB) and Stoke Therapeutics, Inc. (NASDAQ:STOK) collaborated to develop and commercialize zorevunersen for Dravet syndrome in all territories outside the United States ...

Biogen has refueled its R&D engine, paying Stoke Therapeutics $165 million upfront for ex-U.S. rights to a phase 3-ready molecule that could become the first disease-modifying treatment for Dravet ...